Tumor therapy
CA 2483254 A1 · Owner: Diefenbach, Andreas · Inventors: Raulet, David H.; Diefenbach, Andreas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composition may be cells comprising expression constructs for the ligands, liposomes or combinations of proteins molecules.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 31, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 31, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 31, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.